Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHAP Commercial Drug Formulary Coverage & PA | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealth Alliance Plan (HAP)Policy N/A

    Commercial Prescription Drug Formulary and Utilization Management (Pharmacy & Specialty Drugs)

    Customize your policy alerts

    Sign up for all Health Alliance Plan (HAP) policy alerts

    Know when Health Alliance Plan (HAP) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs the prescription drugs covered for Health Alliance Plan (HAP) commercial health plans, including tiers, utilization management (PA, QL, ST), specialty pharmacy requirements, and how to request exceptions or prior authorization. Affects members, prescribers, pharmacies, and specialty pharmacy vendors for HAP commercial plans.

    Policy Summary
    PayerHealth Alliance Plan (HAP)
    PolicyCommercial Prescription Drug Formulary and Utilization Management (Pharmacy & Specialty Drugs)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug is labeled PA and submit required documentation for non-formulary exception requests per HAP process.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    7Tier levels defined (Tier 1-7)
    30 daysTypical specialty supply per fill
    15d/72hPA decision timeframes (std/urgent)
    MultipleNon-Formulary entries
    QLs notedQuantity limits present

    Coverage Criteria and Formulary Controls

    Formulary coverage general criteria

    Covered when requirements below are met

    Formulary coverage general rules: Drug is covered if it appears on the formulary and applicable utilization management (PA, QL, ST) and any specialty pharmacy dispensing requirements are met.

    See specific drug entries for tier, QL, PA, SP designations, and covered alternatives.

    Non-formulary exception criteria

    Non-formulary drugs may be approved when:

    Non-formulary exception: Provider must submit supporting statement that all covered alternatives are either ineffective or would cause harm; HAP clinical specialist reviews for medical necessity and benefit determination.

    If approved, non-formulary generics/brands are billed at highest brand copay; non-formulary specialty billed at highest specialty copay and may require Pharmacy Advantage dispensing; approvals limited to up to 30-day supply.

    Policy Summary
    PayerHealth Alliance Plan (HAP)
    PolicyCommercial Prescription Drug Formulary and Utilization Management (Pharmacy & Specialty Drugs)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug is labeled PA and submit required documentation for non-formulary exception requests per HAP process.
    SourceLink
    On This Page
    Coverage Criteria and Formulary ControlsFormulary Drug Listings and Coding TablesPrior Authorization, Step Therapy, and Dispensing ActionsDispensing Channels and Place-of-Service RulesLegend and Program Code DefinitionsStep Therapy Rules and FlagsQuantity Limits (QL) — Per-Product ExamplesBackground and Scope

    Coverage notes and therapy-specific constraints

    Coverage and limits apply per drug entry; many products are covered for malaria treatment but not prophylaxis as noted.

    Malaria treatment exceptions: Several agents are explicitly 'Covered for Malaria Treatment, not prophylaxis' (e.g., atovaquone-proguanil, chloroquine, hydroxychloroquine, MALARONE/MALARONE PEDIATRIC, mefloquine, PLAQUENIL, primaquine, QUALAQUIN, quinidine, quinine).see individual QL entries

    Refer to each product line for exact QL and PA requirements

    Formulary product-level controls

    Coverage and utilization controls are indicated per-product using listed flags; coverage depends on member benefits and any PA or SP requirements.

    Formulary flags: Each product entry includes a DRUG TIER and NOTES field that may include PA (prior authorization), QL (quantity limits), SP (specialty pharmacy dispensing), ALT (covered alternatives), HCR (Health Care Reform), ST (step therapy), TD (transition fill restriction)

    Use these flags to determine whether additional authorization or specialty dispensing is required

    Formulary controls (observational)

    Coverage and utilization controls observed in this segment

    Formulary tier and control flags: Drugs are assigned formulary tiers (Tier 1-7). Entries include utilization controls such as PA (prior authorization), QL (quantity limits), SP (specialty dispensing), PF (partial fill), MDL/HCR/ALT/AG flags as noted.

    Examples: XIFAXAN shows PA; SP; QL. Many antineoplastics show PA; SP; QL.

    Per-drug formulary coverage conditions

    Coverage determinations per listed drug depend on tier status and noted controls

    Formulary entry requirements: Covered status depends on drug tier and notes. Agents listed as 'Non-Formulary' may still be available via specialty pharmacy but are subject to prior authorization and quantity limits.

    See individual drug entry notes (PA, SP, QL, ALT, PF).

    ACA preventive vaccine coverage

    Preventive vaccine coverage notes

    ACA preventive vaccines covered at zero cost when ACA criteria met: Vaccines annotated with HCR are covered at zero cost share when ACA criteria and plan limits are met; ACA preventive benefit does not apply to Grandfathered Plans.ACA criteria

    Age-specific zero-cost coverage noted for many vaccines (e.g., Gardasil 9 ages 9-45).

    Drugs are excluded from outpatient pharmacy coverage when used for cosmetic purposes, when they are over-the-counter products (unless specifically listed), when they are experimental or used experimentally, or when they are replacements for lost or stolen medication. These exclusions apply across HAP commercial prescription drug benefits; check the member's benefit plan and the Subscriber Contract for plan-specific variations. For drugs that are medical benefit items (administered in a doctor's office or hospital) coverage is managed under the medical benefit rather than the outpatient drug list; specialty medical drugs in that category are coordinated through Pharmacy Advantage.

    Some products in the formulary are designated Non‑Formulary. Examples in the listing include emergency glucagon products (GVOKE), certain naloxone nasal sprays (NARCAN designated Non‑Formulary while other naloxone presentations appear in lower tiers), and allergy/antihistamine agents (e.g., ZERVIATE, ZYRTEC) — these entries indicate they are not on the preferred formulary and may have alternate covered products listed. Non‑Formulary designation generally implies higher member cost‑sharing or the need for an exception request.

    Several specific drug products are listed as Non‑Formulary in the formulary detail. Examples include intravenous agents such as ZEVTERA (ceftaroline) and inhaled/nebulized antibiotics (e.g., TOBI inhalation solution), and antiparasitic/anthelmintic agents like ivermectin (STROMECTOL) which appear as Non‑Formulary in certain strengths. Each Non‑Formulary product line includes notes (e.g., QL, SP, ALT) that indicate any applicable quantity limits, specialty dispensing vendor, or covered alternatives.

    Some formulations and presentations are specifically excluded from standard outpatient pharmacy coverage or are marked Non‑Formulary. Examples in the antifungal and antiviral sections include posaconazole delayed‑release tablets and certain intravenous or oral suspension formulations; many of these entries carry ALT (covered alternatives), PA, and/or QL annotations that dictate coverage conditions and permissible dispensing channels.

    The formulary marks multiple products across therapeutic classes as Non‑Formulary, including select topical, ophthalmic, and systemic agents (examples: BAXDELA, VIGAMOX ophthalmic drops, AZULFIDINE). Where Non‑Formulary status is shown, the entry may also note ALT (covered alternative products), quantity limits, or specialty dispensing requirements that affect how the item may be obtained or whether an exception is needed.

    Palforzia (peanut oral immunotherapy) presentations are listed as Non‑Formulary with specialty dispensing contacts provided (e.g., Optum Specialty, Walgreens Specialty) and supply limits noted. Non‑Formulary designation for Palforzia indicates it is not on the preferred outpatient formulary tier and will follow the plan's non‑formulary exception and specialty dispensing rules.

    Vaccines annotated with HCR are treated as ACA preventive benefits and are covered at zero cost share when ACA criteria and plan limits are met; examples include FLUZONE and GARDASIL‑9 (Gardasil 9 is noted as covered at zero cost for ages 9 through 45 when ACA criteria are satisfied). The formulary explicitly states that the ACA preventive benefit does not apply to Grandfathered Plans.

    Epinephrine auto‑injectors are listed with specific notes: branded devices such as AUVI‑Q, EpiPen and EpiPen Jr appear in the formulary and are marked Non‑Formulary in these entries; quantity limits are specified (e.g., QL = 4 injectors per fill / 4 pens per 30 days). Alternate coverage or covered alternatives are noted where appropriate.

    Additional branded products shown as Non‑Formulary in the listing include certain D‑containing loratadine formulations and other consumer‑facing products; the Non‑Formulary flag signals they are not preferred and may be subject to higher member cost‑sharing or require an exception for coverage.

    Experimental drugs or drugs used in an experimental manner are explicitly excluded from coverage under the outpatient drug list. The formulary does not present explicit 'not medically necessary' (NMN) clinical determinations for listed products in these excerpts; instead, coverage status is conveyed via formulary tier and management flags (e.g., Non‑Formulary, PA, QL, SP), with NMN exclusions limited to experimental use.

    Across the formulary segments provided there are no explicit clinical determinations labeled as 'Not Medically Necessary' beyond the general exclusion for experimental use. Most operational coverage outcomes in the extract are driven by formulary placement and utilization management flags rather than standalone NMN statements.

    Similarly, other parts of the listing use Non‑Formulary status and management annotations (PA, QL, SP) to indicate restricted coverage rather than explicit 'Not Medically Necessary' findings in the text excerpts shown.

    Formulary Drug Listings and Coding Tables

    Prior Authorization, Step Therapy, and Dispensing Actions

    Prior Authorization

    Prior Authorization Required

    Many drugs listed on the formulary require prior authorization (PA) before coverage will be provided. Providers or members must obtain approval from HAP prior to dispensing PA‑marked drugs; without authorization, claims may be denied.

    • PA = Prior Authorization — approval required before fill; lack of PA may result in denial
    • PA-marked drugs across the formulary require submission of an authorization request prior to dispensing
    • Examples of PA triggers in the formulary: certain antivirals, antifungals, inhaled tobramycin products, many specialty oncology and immunoglobulin agents (see formulary notes)
    Prior Authorization

    Prior Authorization for Specialty/Channel Dispensing

    Many specialty agents and non-formulary specialty products require prior authorization and may also be limited to dispensing through a specialty channel (Pharmacy Advantage or named specialty/vendor). When a specialty dispensing requirement (SP) applies, the drug must be obtained from the listed vendor (e.g., Pharmacy Advantage: 800-456-2112; Home Infusion: 800-884-1474; Cardinal Specialty 866-677-4844; MMS Solutions 866-716-5486). Failure to use the required specialty channel may lead to claim denial or non-coverage.

    • Many specialty drugs = PA + SP (dispensed by Pharmacy Advantage or specified vendor)
    • If authorized as a non-formulary specialty drug, plan may require specialty channel dispensing and will bill at highest specialty copay
    • Specialty drugs often limited to a 30‑day supply per fill when dispensed via specialty vendor
    Billing Rule

    Formulary Restrictions and Utilization Controls

    Formulary controls include PA (prior authorization), QL (quantity limits), ST (step therapy), SP (specialty dispensing), HCR (ACA/preventive rules), TD (new member fill restrictions), PF (partial fill), and AG (age restrictions). Providers should review the formulary notes on each product for specific utilization controls and program codes before submitting a claim or prior authorization request.

    • QL = Quantity Limits — per fill or per time period (examples shown per drug notes)
    • ST = Step Therapy — may require trial of specified alternatives before coverage
    • HCR = Health Care Reform/ACA preventive documentation required for zero cost-share
    • TD = Limited first fills for new members (TF/TD examples noted in formulary legend)
    Prior Authorization

    Specific Product Limits and Prior Authorization Examples

    Specific products listed in the formulary carry explicit PA and/or QL notations. Examples include (not exhaustive): tobramycin inhalation solutions (PA; SP; QL), certain antifungals (voriconazole: PA; QL), PAXLOVID (PA; QL — 5 days/180 days), DESCOVY (PA; QL 1 tablet/day), many oncology and hepatitis agents (PA; SP; QL). Check the drug-specific notes for the exact PA, SP, QL, PF and TF/TD flags.

    • Tobramycin inhalation products: PA; SP (Pharmacy Advantage); QL (ampules per 30 days)
    • PAXLOVID: PA; QL (5-day treatment per 180 days)
    • DESCOVY and related antiretrovirals: PA; QL (1 tablet per day); HCR flags for preventive use
    Denial Risk

    Prior Authorization and Non‑Formulary Risk / Exceptions

    Non‑formulary drugs present additional risk of non-coverage unless an exception is granted. Providers may request a non‑formulary exception by submitting clinical documentation supporting medical necessity. If approved, non‑formulary drugs may be limited (e.g., 30‑day supply) and specialty non‑formulary approvals may require specialty dispensing and higher copay tiers.

    • Submit non-formulary exception or PA forms to HAP Pharmacy Care Management (mail/fax) or via hap.org
    • Non-formulary approvals for brand or specialty drugs billed at highest applicable copay
    • Non-formulary specialty approvals commonly limited to 30-day supply per fill
    Documentation Required

    Required Documentation and Program Codes for PA/Exceptions

    When submitting PA or non-formulary exception requests, include required documentation and program codes: clinical rationale, supporting statement from the prescriber, diagnosis, prior therapy and outcomes, dosing and anticipated duration, and any relevant lab or imaging results. Use program legends (PA, QL, SP, ST, TD, PF, AG, HCR) to document the request and indicate any specialty vendor routing required.

    • Required documentation: prescriber statement of medical necessity, prior treatment attempts, supporting clinical records
    • Include formulary program codes (PA, QL, SP, ST, HCR, TD, PF, AG) on requests to ensure correct handling
    • For specialty or home-infusion requests, indicate requested dispensing vendor and site of administration (if applicable)
    Note

    Prior Authorization Timing and Decisionframes

    Timeframes and decision windows: standard prior authorization decisions are completed within 15 calendar days of receiving a request; urgent authorization requests must be decided within 72 hours. Non‑formulary exception decisions are completed within 72 hours (or 24 hours if urgent). Providers should mark urgent requests clearly and supply supporting clinical rationale.

    • Standard PA decision: within 15 calendar days
    • Urgent PA decision: within 72 hours
    • Non‑formulary exception decision: within 72 hours (24 hours if urgent)
    Step Therapy

    Therapy Step and New‑Member Fill Restrictions

    Therapy-step and new member fill restrictions (ST, TF/TD): some items require step therapy (trial of preferred agents) and/or are limited for new members to a single 30‑day fill during the first 90 days of enrollment. Check TF/TD flags and ST indicators on product entries before dispensing to avoid denial.

    • ST = Step Therapy — must fail or have contraindication to required alternatives
    • TD / TF = For new members: one 30‑day fill in first 90 days may apply
    • Claims for ST/TD items without appropriate history or PA are at risk of denial

    Dispensing Channels and Place-of-Service Rules

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Legend and Program Code Definitions

    inv-124: Specialty drugs definition
    Specialty drugs — definitionBiologics or prescription drugs that require special handling, provider coordination and patient education; often require prior authorization and are dispensed by a contracted specialty pharmacy (Pharmacy Advantage).
    Specialty dispensing contactPharmacy Advantage: (800) 456-2112 — specialty drugs often limited to up to 30 supply per fill
    Use of specialty vendorSome specialty/home infusion items dispensed by named vendors (Fairlane HFHS Home Infusion, Optum Specialty, Walgreens Specialty)
    inv-125: Tier definitions (Tier 1–7 overview)
    Tier definitions (overview)Tier 1 = Select Generic; Tier 2 = Generic & Select Brand; Tier 3 = Preferred Brand; Tier 4 = Non‑Preferred Brand/Generic; Tier 5 = Preferred Specialty; Tier 6 = Non‑Preferred Specialty; Tier 7 = Medical Coinsurance
    Tier implicationsTiers indicate formulary placement and relative member cost‑sharing
    Specialty tiersPreferred Specialty (Tier 5) and Non‑Preferred Specialty (Tier 6) include many specialty oral and injectable agents
    inv-126: Legend abbreviations (PA, QL, SP, ALT, MDL)
    PAPrior Authorization
    QLQuantity Limits
    SPSpecialty dispensing (drug must be obtained from designated specialty pharmacy/vendor)
    inv-127: PA abbreviation (short)
    PAPrior Authorization
    UsageAuthorization required before coverage for specified products
    Source noteAppears in formulary legend and on product rows
    inv-128: QL abbreviation (short)
    QLQuantity Limits
    UsageMaximum quantity allowed in specified time frame as listed per product
    Source noteUsed on product rows to control dispensing and claims
    inv-129: SP abbreviation (specialty dispensing)
    SPSpecialty dispensing — drug must be obtained from specified specialty pharmacy (e.g., Pharmacy Advantage)
    ContactPharmacy Advantage: (800) 456-2112; other vendors listed per product
    Supply noteSP entries commonly note up to a 30 supply per fill
    inv-130: ST abbreviation (therapy required step)
    STST = Therapy Required Step (step therapy)
    UsageIndicates trial of specified alternative(s) required before coverage
    Legend noteDefined in formulary legend; specific product lines show ST where applicable
    inv-131: TD abbreviation (transition rule for new members)
    TDTD = Transition rule for new HAP members (one 30‑day fill in first 90 days)
    UsageApplied to select products for new‑to‑plan members
    Legend placementShown in formulary legend and product notes (TF/TD/ST flags)
    inv-132: PA definition (expanded)
    PA (expanded)Prior Authorization — approval required before coverage for specified products; standard decision within 15 calendar days, urgent within 72 hours
    Operational noteProviders must submit PA documentation per HAP process
    Specialty drugsSpecialty drugs generally require PA and may need specialty dispensing
    inv-133: QL definition (expanded)
    QL (expanded)Quantity Limits — maximum quantity allowed in specified time frame (per day, per fill, per 28/30 days) as noted on product rows
    DocumentationClaims/prescriptions should indicate days' supply and quantity consistent with QL
    Denial riskExceeding QL may trigger claim denial or require PA
    inv-134: SP definition (expanded)
    SP (expanded)Specialty dispensing — drug must be obtained from designated specialty pharmacy/vendor (e.g., Pharmacy Advantage, Fairlane HFHS Home Infusion); vendor contact often provided
    Supply limitSP entries commonly limit up to a 30 supply per fill
    Fulfillment noteFailure to use required specialty dispenser may affect coverage
    inv-135: PA definition (alternate chunk)
    PA (alt) Prior Authorization — authorization required before coverage (alternate wording)
    ContextAppears repeatedly in legend and product notes
    Provider actionObtain PA prior to dispensing when PA flag present
    inv-136: QL definition (alternate chunk)
    QL (alt)Quantity Limits — maximum quantity allowed per time period; shown as per day, per fill, per 28/30 days
    ExamplesMany entries show QL values (e.g., 10 capsules per fill; 120 capsules per 30 days)
    Operational impactClaims must reflect QL or may be denied/edited
    inv-137: SP definition (alternate chunk)
    SP (alt)Specialty dispensing — drug must be dispensed by Pharmacy Advantage or specified vendor; phone numbers provided on product lines
    RoutingPrescriptions should be routed to the specified specialty dispenser when SP is noted
    SupplyUp to 30 supply per fill commonly enforced
    inv-138: ALT (Covered Alternatives) definition
    ALT (Covered Alternatives)Covered Alternatives — formulary preferred alternatives listed when an item is Non‑Formulary; used to support exceptions or substitution
    UsageALT entries appear on product rows to indicate acceptable covered substitutes
    Exception implicationNon‑Formulary items may have ALT suggestions for coverage consideration
    inv-139: PA (definition duplicate)
    PA (duplicate)Prior Authorization — approval required prior to coverage
    NoteRepeated in legend and documentation modules
    Provider requirementSubmit PA per HAP instructions
    inv-140: QL (definition duplicate)
    QL (duplicate)Quantity Limits — specified maximum quantity in a timeframe
    ExamplesShown across many product lines (per day, per fill, per 30 days)
    EnforcementExceeding QL may trigger denial or PA requirement
    inv-141: SP (definition duplicate)
    SP (duplicate)Specialty dispensing via Pharmacy Advantage or other named specialty vendors — required for SP‑flagged drugs
    Contact infoPharmacy Advantage: (800) 456-2112; other vendor numbers listed per product
    Supply limitCommonly limited to up to 30 supply per fill
    inv-142: Tier (definition duplicate)
    Tier (duplicate)Formulary tiers 1–7 indicate coverage and cost‑sharing categories
    ImplicationTiers inform member cost shares and utilization controls applied
    ReferenceTier definitions appear in legend and across product listings
    inv-143: SP — Pharmacy Advantage dispensing only note
    SP — Pharmacy Advantage dispensing only noteSome drugs can only be obtained at Pharmacy Advantage (800‑456‑2112) and are limited to up to a 30 supply per fill
    Operational impactClaims from other channels may be denied if SP requirement not met
    Provider actionUse designated specialty vendor when SP is indicated
    inv-144: QL (definition duplicate)
    QL (duplicate short)Quantity Limits — maximum allowed per specified timeframe
    Provider noteDocument days' supply and quantity consistent with QL when submitting claims/PA
    Claim riskExceeding QL can trigger edits/denials
    inv-145: PA (definition duplicate)
    PA (definition duplicate)Prior Authorization — approval required before coverage
    TimeframesStandard PA decisions within 15 calendar days; urgent decisions quicker per policy
    DocumentationSubmit required clinical/supporting documentation for PA requests
    inv-146: PA (definition duplicate)
    PA (definition duplicate)Prior Authorization — authorization required before coverage
    UseIndicated on product rows where coverage requires prior approval
    Provider actionObtain PA prior to dispensing when PA flag present
    inv-147: QL (definition duplicate)
    QL (duplicate)Quantity Limits — maximum quantity allowed per product timeframe
    ExamplesValues shown as per day, per fill, per 30 days across product entries
    ActionFollow QL when submitting claims or PA requests
    inv-148: SP (definition duplicate)
    SP (duplicate)Specialty dispensing — drug must be dispensed by designated specialty pharmacy/vendor
    Vendor examplesPharmacy Advantage, Optum Specialty, Walgreens Specialty, Accredo, Fairlane HFHS Home Infusion
    Supply noteSP entries often indicate up to 30 supply per fill
    inv-149: Abbreviations used in formulary entries (summary)
    Common abbreviations used in formulary entriesPA = Prior Authorization; QL = Quantity Limits; SP = Specialty dispensing; PF = Partial Fill Program; HCR = Health Care Reform; ST = Therapy Required Step; TD = Transition fill; ALT = Covered Alternatives; AG = Age Restriction
    PurposeAbbreviations annotate product-level utilization controls and coverage rules
    Provider actionFollow the annotated program codes when processing claims or PA requests
    inv-150: Specialty dispensing only via designated pharmacy note
    Specialty dispensing only via designated pharmacySP entries require dispensing via designated specialty pharmacies (e.g., Pharmacy Advantage: 800‑456‑2112; Fairlane HFHS Home Infusion: 800‑884‑1474)
    Supply limitCommonly limited to up to a 30 supply per fill
    ExceptionHome infusion may be used if criteria met and requested for home administration
    inv-151: Program codes summary
    Program codes summaryPA = Prior Authorization; QL = Quantity Limits; SP = Specialty dispensing; HCR = Health Care Reform; ST = Therapy Required Step; PF = Partial Fill Program; TD = Transition fill; ALT = Covered Alternatives
    UseCodes appear in product NOTES fields to indicate utilization controls
    Provider guidanceFollow these codes when submitting PA or exception requests
    inv-152: Health Care Reform (HCR) definition
    HCR (Health Care Reform) — vaccinesHCR = ACA preventive benefit notes; vaccines annotated HCR are covered at zero cost share when ACA criteria and plan limits are met
    LimitationACA preventive benefit does not apply to Grandfathered Plans
    ExamplesGardasil‑9, Shingrix entries include HCR annotations with age‑based coverage
    inv-153: Policy program codes list
    Policy program codes listPA, QL, SP, HCR, ST, TD, PF, ALT, AG — used throughout formulary to indicate coverage controls
    Operational noteProviders should reference product NOTES for applicable program codes
    ImpactCodes determine PA needs, dispensing vendor, limits, and special handling
    inv-154: Formulary tier definitions (detailed)
    Formulary tier definitions (detailed)Tier 1 = Select Generic; Tier 2 = Generic & Select Brand; Tier 3 = Preferred Brand; Tier 4 = Non‑Preferred Brand & Generic; Tier 5 = Preferred Specialty; Tier 6 = Non‑Preferred Specialty; Tier 7 = Medical Coinsurance
    Specialty tiersTier 5–6 include specialty agents often requiring PA and SP
    Medical drugsTier 7 covers drugs administered in medical setting (medical benefit)
    inv-155: Abbreviations — contact info and supply limits
    Abbreviations — contact & supply limitsSP entries include Pharmacy Advantage contact (800‑456‑2112) and commonly note up to a 30 supply per fill; PA = Prior Authorization; QL = Quantity Limits
    Provider actionDocument vendor contact and follow supply limits on claims/PA
    ReferenceLegend and Notes sections include these abbreviations consistently

    Step Therapy Rules and Flags

    Policy itemSummary / definitionApplies where noted
    Step therapy (ST)Requires trial and failure of specified alternative agent(s) before the requested drug will be covered.Status: neutral — applies to formulary entries marked 'ST'
    ST presence on formulary entriesST is indicated in formulary legend as 'Therapy Required Step' and denotes where step edits apply.Status: neutral — applies where 'ST' appears on drug lines
    Legend codeMeaning
    STTherapy Required Step (step therapy)
    ReferenceInterpretationWhere to look
    Formulary legend entryST is defined in the legend as Therapy Required Step and applies to drug lines marked 'ST'.Drug-level NOTES field where 'ST' appears
    ObservationImplicationCoverage label
    ST flag present on some productsIndicates a therapy-required step per HAP policy — providers must document prior trials of required agents when requesting coverage for the ST drug.Status: neutral
    NoteWhat is includedLimitations in excerpt
    ST indicated in legendLegend lists ST = Therapy Required Step to denote step therapy program.Specific step rules and product-specific step sequences are not detailed in this excerpt.
    FlagEffect on coverageEvidence in document
    ST flagIndicates a therapy-required step may apply for some drugs; coverage contingent on following step therapy rules when present.Formulary notes and legend referencing ST codes
    IndicatorMeaningAction for providers
    ST flag on drug lineDenotes that a therapy-required step applies for that product (step therapy).Providers should document prior trials/failures of required agents per PA/step-therapy process when submitting prior authorization or override requests.
    Legend itemDefinitionCitation
    STTherapy Required StepDefined in formulary legend
    FindingConsequenceNotes
    ST flag present for certain drugsWhere present, step therapy requirements govern coverage; specific step sequences are located on individual drug lines elsewhere in the full formulary.Excerpt does not list the step sequences themselves
    AbbreviationExpandedUse
    STTherapy Required StepUsed in legend to identify drugs subject to step therapy edits
    PatternInterpretationProvider implication
    ST noted on some drug linesIndicates step-therapy requirement prior to coverage of that drug. Specific step requirements are on product lines where 'ST' appears.Providers must follow step therapy process and supply documentation of prior agent trials when requested.
    Legend presenceMeaning for coverageLimitations
    ST in legendIndicates therapy-required step program exists and applies to drugs marked 'ST'.The excerpt does not enumerate the required prior agents or failure criteria for each ST-marked product.
    FlagOperational effectDocumentation
    ST flagMay require documented trial/failure of specified alternatives before covering the requested therapy.Document prior medication history and any PA forms when submitting exceptions or authorization requests.
    Flags in notesImplication for new-to-HAP membersExample
    TF / TD / ST flagsDenote therapy-step or limited-fill rules for new-to-HAP members; TD/TF may limit initial fills (e.g., one 30-day fill within first 90 days of enrollment).Example: TRELEGY — TF (one 30-day fill in first 90 days) noted in product NOTES.
    TF / TD exampleRestrictionContext
    TF / TD new-member fill restrictionsFor new-to-HAP members these flags can limit initial supply to one 30-day fill during the first 90 days of enrollment.Documented on specific drug NOTES (e.g., carvedilol phosphate ER marked TF; TRELEGY marked TF in product NOTES).

    Quantity Limits (QL) — Per-Product Examples

    Background and Scope

    Background: Specialty drugs are biologics or other prescription medications that typically require special handling, provider coordination, and patient education. They are frequently dispensed via designated specialty pharmacies (for example, Pharmacy Advantage) and commonly subject to utilization management controls such as Prior Authorization (PA), Quantity Limits (QL), and specialty dispensing (SP). The formulary groups drugs by therapeutic category and annotates each product line with tier, PA/QL/SP flags, covered alternatives (ALT), and any age or new‑member transition restrictions.